Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
Non-Nucleoside Reverse Transcriptase Inhibitors
Glossary of Terms for Supplement
Carcinogenic= producing or tending to produce cancer
Clastogenic= causing disruption of or breakages in chromosomes
Five non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) are currently approved: delavirdine, efavirenz, etravirine, nevirapine and rilpivirine. Delavirdine is no longer available in the United States.
For information about potential interactions between NNRTIs and methergine, see the Postpartum Hemorrhage, Antiretroviral Drugs, and Methergine Use sections.
Delavirdine (Rescriptor, DLV)
Efavirenz (Sustiva, EFV)
Etravirine (Intelence, ETR)
Nevirapine (Viramune, NVP)
Rilpivirine (Edurant. RPV)